<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753220</url>
  </required_header>
  <id_info>
    <org_study_id>CRITICAL001</org_study_id>
    <nct_id>NCT00753220</nct_id>
  </id_info>
  <brief_title>Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer</brief_title>
  <acronym>CRITICAL</acronym>
  <official_title>A Phase I/IIa Trial of Combined Cryotherapy and Intra-tumoral Immunotherapy With Autologous Immature Dendritic Cells (VDC2008) in Chemo-naïve Men With Prostatic Adenocarcinoma and Limited Metastases to Lymph Nodes and/or Bone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bostwick Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prostate Institute of America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Community Memorial HealthCenter</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HemaCare Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bostwick Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the intra-tumoral injection of a subject's own&#xD;
      dendritic cells after cryotherapy of the prostate is a safe and effective treatment for&#xD;
      advanced prostate cancer.&#xD;
&#xD;
      In theory, the injected dendritic cells will internalize antigens from the tumor cells which&#xD;
      have been damaged by cryotherapy and activate the subject's immune system against that&#xD;
      specific tumor.&#xD;
&#xD;
      Subjects will also receive a low dose chemotherapy designed to lower the number of&#xD;
      T-regulatory cells which have been shown to lower or stop some immune system responses.&#xD;
&#xD;
      Hypothesis 1: Dendritic cell injection into cryotreated prostate cancer is non-toxic;&#xD;
&#xD;
      Hypothesis 2: Dendritic cell injection into cryotreated prostate cancer is medically&#xD;
      beneficial to the subject.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study treatment dendritic cells (VDC2008) will be injected into the prostate following&#xD;
      prostatic cryoablation. It is speculated that antigen from the cryoablated cancer will be&#xD;
      available in the vicinity of the cryoablation field immediately following the procedure.&#xD;
      Autologous, immature dendritic cells are capable of internalizing antigen, migrating to the&#xD;
      lymphatic system, and presenting antigenic epitopes to T lymphocytes. In this way, dendritic&#xD;
      cells are capable of initiating a cell-mediated systemic immune response.&#xD;
&#xD;
      In concept, the cancer itself should provide a specific and potentially broad spectrum of&#xD;
      cancer-related antigens. Regulatory T lymphocytes, which have been implicated in dampening or&#xD;
      halting cell-mediated, antigen-specific immune responses, will be selectively depleted using&#xD;
      a regimen of low-dose cyclophosphamide. Low-dose cyclophosphamide has been empirically shown&#xD;
      to selectively deplete the number of circulating regulatory T cells.&#xD;
&#xD;
      Using this combination of therapies, it is thought that a clinically significant anti-cancer&#xD;
      immune response might be elicited.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrew the IND with the FDA.&#xD;
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>PROTOCOL EXCERPT: The primary objective of the Phase I Portion of this study is the determination of the maximum tolerated dose (MTD) of intratumorally injected study agent VDC2008 administered following cryoablation of the prostate, and pre- and post-treatment with a low-dose cyclophosphamide therapy, as determined by toxicity and adverse event monitoring following treatment of metastatic androgen-independent prostate cancer.&#xD;
ADDITIONAL INFORMATION: MTD was not reached by any study participant prior to end of the study. Additional participants would have been necessary to determine MTD.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>VDC2008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cryoablation of prostate followed by dendritic cell injection (dose of 2.5 x 10^7, 7.5 x 10^7, or 1.0 x 10^8 cells depending on assigned cohort) into prostate and low dose cyclophosphamide therapy (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles [1 cycle = 4 weeks] starting Week 2 after cryoablation and going to Week 26)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VDC2008</intervention_name>
    <description>Intratumoral injection of VDC2008 post-cryotherapy.&#xD;
Dosage will depend on cohort: 2.5 x 10^7, 7.5 x 10^7 or 1.0 x 10^8 cells</description>
    <arm_group_label>VDC2008</arm_group_label>
    <other_name>Autologous dendritic cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide i.v. given at day -3 (dose: 300mg/m2); Low-dose Cyclophosphamide pill given twice daily (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles [1 cycle = 4 weeks] starting Week 2 after cryoablation and going to Week 26)</description>
    <arm_group_label>VDC2008</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Men ≥ 18 years of age and any race.&#xD;
&#xD;
          -  Signed Informed Consent document obtained prior to the initiation of screening&#xD;
             procedures.&#xD;
&#xD;
          -  Histologically documented primary adenocarcinoma of the prostate. A specimen of the&#xD;
             primary tumor must be submitted to the Central Pathology Laboratory for confirmation&#xD;
             of prostatic adenocarcinoma and determination of Gleason Sum grading.&#xD;
&#xD;
          -  Prior history of:&#xD;
&#xD;
               1. Androgen Deprivation Therapy; or&#xD;
&#xD;
               2. Organ-preserving therapy (i.e., non-prostatectomy) for primary prostate cancer&#xD;
                  (e.g., radiation therapy).&#xD;
&#xD;
          -  In case of recurrence, subject must have evidence of prostate cancer by a positive&#xD;
             biopsy revealing adenocarcinoma within the past 6 months of screening and confirmed by&#xD;
             the Central Pathology Laboratory.&#xD;
&#xD;
          -  TxNxM1a and/or TxNxM1b disease limited to three total metastatic sites as evidenced by&#xD;
             lymph node metastases and /or bone metastases at time of screening.&#xD;
&#xD;
               1. TxNxM1a : Lymph node metastases histologically proven and confirmed by Central&#xD;
                  Pathology Laboratory;&#xD;
&#xD;
               2. TxNxM1a: Lymph node metastases not histologically proven, given that the&#xD;
                  following are satisfied in the temporal order listed:&#xD;
&#xD;
                    1. Computed tomography (CT) or Magnetic Resonance Imaging (MRI) for positive&#xD;
                       lymph nodes negative at original diagnosis of prostate cancer;&#xD;
&#xD;
                    2. Definitive local treatment undertaken;&#xD;
&#xD;
                    3. Evidence of local treatment failure on the basis of rising serum PSA;&#xD;
&#xD;
                    4. Prostatic biopsy positive for carcinoma;&#xD;
&#xD;
                    5. Subsequent CT or MRI reveals lymph node(s) of 2 cm diameter or greater&#xD;
&#xD;
               3. TxNxM1b: Bone metastases demonstrated by radionuclide bone scan, CT, or MRI.&#xD;
&#xD;
          -  Androgen-independent prostate cancer as defined by:&#xD;
&#xD;
               1. Three consecutive rises of at least 10% each in serum PSA, in which all serum PSA&#xD;
                  measurements are separated by at least one week and results are obtained within&#xD;
                  60 days of study screening; OR&#xD;
&#xD;
               2. Three rises that involve an increase of 50% over the nadir serum PSA, in which&#xD;
                  all serum PSA measurements are separated by at least one week and results are&#xD;
                  obtained within 60 days of study screening;&#xD;
&#xD;
               3. A castrate level of testosterone (&lt;50 ng/dl) obtained within 60 days of study&#xD;
                  screening.&#xD;
&#xD;
          -  Life expectancy of greater than or equal to 12 months.&#xD;
&#xD;
          -  Adequate hematological function as defined by:&#xD;
&#xD;
               1. Total WBC &gt; 4,500/mm3&#xD;
&#xD;
               2. Total lymphocyte count &gt; 500/mm3&#xD;
&#xD;
               3. Hemoglobin &gt; 12.0 g/dl&#xD;
&#xD;
               4. Neutrophils &gt; 1,500/mm3&#xD;
&#xD;
               5. Platelets &gt; 150,000/mm3&#xD;
&#xD;
          -  Adequate renal function with creatinine &lt; 2.0 mg/dl.&#xD;
&#xD;
          -  Adequate liver function as defined by:&#xD;
&#xD;
               1. AST and ALT &lt; 2 times the upper limit of normal;&#xD;
&#xD;
               2. Serum bilirubin &lt; 2.0 mg/dl;&#xD;
&#xD;
               3. Alkaline Phosphatase &lt; 2.0 upper limit of normal.&#xD;
&#xD;
          -  Assessment of superficial veins as adequate for the performance of leukapheresis.&#xD;
&#xD;
          -  No active major medical or psychological problems that could be complicated by study&#xD;
             participation.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  The presence of lung, liver or brain metastases, malignant pleural effusions or&#xD;
             malignant ascites.&#xD;
&#xD;
          -  Moderate or severe symptomatic metastatic disease. Subjects who meet either of the&#xD;
             following criteria must be excluded:&#xD;
&#xD;
               1. A requirement for treatment with opioid analgesics for any reason within 21 days&#xD;
                  prior to study screening;&#xD;
&#xD;
               2. Average weekly pain score of 4 or more as reported on the 11-point Pain Intensity&#xD;
                  - Numerical Rating Scale (Appendix III) over the two weeks prior to study&#xD;
                  enrollment.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2 accessed at study&#xD;
             screening visit.&#xD;
&#xD;
          -  Chemotherapy treatment at any time prior to study screening.&#xD;
&#xD;
          -  Radiation therapy for metastatic disease, including intravenous radioactive strontium&#xD;
             therapy.&#xD;
&#xD;
          -  Initiation or discontinuation of bisphosphonate therapy within 28 days prior to study&#xD;
             screening. Subjects taking bisphosphonate medication must not have their dosing&#xD;
             regimen altered until objective disease progression is independently confirmed.&#xD;
&#xD;
          -  Treatment with any of the following medications or interventions within 28 days of&#xD;
             study screening:&#xD;
&#xD;
               1. Systemic corticosteroids (use of inhaled, intranasal and topical steroids is&#xD;
                  acceptable);&#xD;
&#xD;
               2. External beam radiation therapy or surgery;&#xD;
&#xD;
               3. PC-SPES (or PC-SPEC) or Saw Palmetto extract;&#xD;
&#xD;
               4. Megestrol acetate (Megace®), diethyl stilbesterol (DES), or cyproterone acetate;&#xD;
&#xD;
               5. Ketoconazole;&#xD;
&#xD;
               6. High dose calcitriol (i.e., &gt; 7.0 μg/week);&#xD;
&#xD;
               7. Any other systemic therapy for prostate cancer.&#xD;
&#xD;
          -  Treatment with any investigational vaccine within 2 years of enrollment to this study.&#xD;
&#xD;
          -  Treatment with any other investigational product within 28 days of study screening.&#xD;
&#xD;
          -  Pathologic long-bone fractures, imminent pathologic long-bone fracture (cortical&#xD;
             erosion on radiography &gt; 50%) or spinal cord compression.&#xD;
&#xD;
          -  Impending untreated spinal cord compression or urinary outlet obstruction.&#xD;
&#xD;
          -  Paget's Disease of bone.&#xD;
&#xD;
          -  History of stage III or greater cancer, excluding prostate cancer:&#xD;
&#xD;
               1. Basal or squamous cell skin cancers must have been adequately treated and the&#xD;
                  subject must be disease-free at the time of study screening visit;&#xD;
&#xD;
               2. Subjects with a history of stage I or II cancer must have been adequately treated&#xD;
                  and be disease-free for ≥ 3 years at the time of study screening&#xD;
&#xD;
          -  Requirement for systemic immunosuppressive therapy for any reason&#xD;
&#xD;
          -  Prior or currently active autoimmune disease requiring management with systemic&#xD;
             immunosuppression. Such conditions include inflammatory bowel disease, systemic&#xD;
             vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia,&#xD;
             immune-related thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus,&#xD;
             Sjögren's syndrome, sarcoidosis, or other rheumatological disease.&#xD;
&#xD;
          -  Any infection requiring parenteral antibiotic therapy or causing fever (body&#xD;
             temperature &gt; 100.5°F or 38.1°C) within 1 week prior to study screening.&#xD;
&#xD;
          -  Known allergy, intolerance, or medical contraindication to receiving the contrast dye&#xD;
             required for the protocol-specified CT imaging&#xD;
&#xD;
          -  History of asthma, anaphylaxis, or other known serious adverse reactions to vaccines.&#xD;
&#xD;
          -  Any medical intervention or other condition which, in the opinion of the&#xD;
             Physician-Investigator could compromise adherence with study requirements or otherwise&#xD;
             compromise study subject safety and the study's objectives.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duke K Bahn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prostate Institue of America</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Community Memorial Hospital</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>September 12, 2008</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <results_first_submitted>July 25, 2013</results_first_submitted>
  <results_first_submitted_qc>November 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2014</results_first_posted>
  <last_update_submitted>November 3, 2014</last_update_submitted>
  <last_update_submitted_qc>November 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Androgen</keyword>
  <keyword>Independent</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>(AIPC),</keyword>
  <keyword>Hormone-refractory</keyword>
  <keyword>(HRPC),</keyword>
  <keyword>cryotherapy,</keyword>
  <keyword>dendritic cell,</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>Chemo-naïve</keyword>
  <keyword>lymph nodes</keyword>
  <keyword>bone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Men at least 18 years of age diagnosed with prostate cancer with metastases limited to three sites (e.g., lymph nodes and/or bone) who have been determined to have undergone progression of their cancer under androgen blockade (i.e., are androgen-independent) will be eligible for this study.</recruitment_details>
      <pre_assignment_details>Prior to any screening evaluations, the purpose of the study &amp; study related tests/procedures will be explained, then subject signs ICF. Subject will undergo screening assessments to determine if he meets all of the inclusion criteria &amp; none of the exclusion criteria. Screen failures will not be eligible for re-screening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>VDC2008</title>
          <description>Cryoablation of prostate followed by dendritic cell injection into prostate and low dose cyclophosphamide therapy&#xD;
VDC2008 : Intratumoral injection of VDC2008 post-cryotherapy.&#xD;
Dosage will depend on cohort: 2.5 x 10^7, 7.5 x 10^7 or 1.0 x 10^8</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VDC2008</title>
          <description>Cryoablation of prostate followed by dendritic cell injection into prostate and low dose cyclophosphamide therapy&#xD;
VDC2008 : Intratumoral injection of VDC2008 post-cryotherapy.&#xD;
Dosage will depend on cohort: 2.5 x 10^7, 7.5 x 10^7 or 1.0 x 10^8</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD)</title>
        <description>PROTOCOL EXCERPT: The primary objective of the Phase I Portion of this study is the determination of the maximum tolerated dose (MTD) of intratumorally injected study agent VDC2008 administered following cryoablation of the prostate, and pre- and post-treatment with a low-dose cyclophosphamide therapy, as determined by toxicity and adverse event monitoring following treatment of metastatic androgen-independent prostate cancer.&#xD;
ADDITIONAL INFORMATION: MTD was not reached by any study participant prior to end of the study. Additional participants would have been necessary to determine MTD.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VDC2008</title>
            <description>Cryoablation of prostate followed by dendritic cell injection into prostate and low dose cyclophosphamide therapy&#xD;
VDC2008 : Intratumoral injection of VDC2008 post-cryotherapy.&#xD;
Dosage will depend on cohort: 2.5 x 10^7, 7.5 x 10^7 or 1.0 x 10^8</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD)</title>
          <description>PROTOCOL EXCERPT: The primary objective of the Phase I Portion of this study is the determination of the maximum tolerated dose (MTD) of intratumorally injected study agent VDC2008 administered following cryoablation of the prostate, and pre- and post-treatment with a low-dose cyclophosphamide therapy, as determined by toxicity and adverse event monitoring following treatment of metastatic androgen-independent prostate cancer.&#xD;
ADDITIONAL INFORMATION: MTD was not reached by any study participant prior to end of the study. Additional participants would have been necessary to determine MTD.</description>
          <units>intratumorally delivered cells</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">MTD was not reached by any study participant prior to end of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Overall Study (1 year, 2 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>VDC2008</title>
          <description>Cryoablation of prostate followed by dendritic cell injection into prostate and low dose cyclophosphamide therapy&#xD;
VDC2008 : Intratumoral injection of VDC2008 post-cryotherapy.&#xD;
Dosage will depend on cohort: 2.5 x 10^7, 7.5 x 10^7 or 1.0 x 10^8</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Heartburn</sub_title>
                <description>Mild heartburn</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of Appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Memory</sub_title>
                <description>Memory Problem from General Anesthesia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Duke K. Bahn</name_or_title>
      <organization>Prostate Institute of America</organization>
      <phone>888-234-0004</phone>
      <email>DKBahn@CMHhospital.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

